Literature DB >> 17516698

Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial.

K Nishitsuji1, H To, Y Murakami, K Kodama, D Kobayashi, T Yamada, C Kubo, K Mine.   

Abstract

Entities:  

Year:  2004        PMID： 17516698     DOI： 10.2165/00044011-200424020-00007

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  20 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  Buspirone augmentation of antidepressant therapy.

Authors:  E C Dimitriou; C E Dimitriou
Journal:  J Clin Psychopharmacol       Date:  1998-12       Impact factor: 3.153

Review 3.  The use and development of anxiolytics in Japan.

Authors:  S Yamawaki
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

4.  Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

Authors:  Karl Rickels; Rocco Zaninelli; James McCafferty; Kevin Bellew; Malini Iyengar; David Sheehan
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

5.  Comparison of buspirone and diazepam in generalized anxiety disorder.

Authors:  A F Jacobson; R A Dominguez; B J Goldstein; R M Steinbook
Journal:  Pharmacotherapy       Date:  1985 Sep-Oct       Impact factor: 4.705

6.  An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.

Authors:  R T Joffe; D R Schuller
Journal:  J Clin Psychiatry       Date:  1993-07       Impact factor: 4.384

Review 7.  Do benzodiazepines have a role in the prevention or treatment of coronary heart disease and other major medical disorders?

Authors:  R B Williams
Journal:  J Psychiatr Res       Date:  1990       Impact factor: 4.791

8.  Buspirone and diazepam in anxiety: a controlled study.

Authors:  K Rickels; K Weisman; N Norstad; M Singer; D Stoltz; A Brown; J Danton
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

9.  Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites.

Authors:  A Hamik; D Oksenberg; C Fischette; S J Peroutka
Journal:  Biol Psychiatry       Date:  1990-07-15       Impact factor: 13.382

10.  Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone.

Authors:  S M Murphy; R Owen; P Tyrer
Journal:  Br J Psychiatry       Date:  1989-04       Impact factor: 9.319
View more
  8 in total

Review 1.  Contextual conditioning in rats as an animal model for generalized anxiety disorder.

Authors:  Laura Luyten; Debora Vansteenwegen; Kris van Kuyck; Loes Gabriëls; Bart Nuttin
Journal:  Cogn Affect Behav Neurosci       Date:  2011-06       Impact factor: 3.282

2.  Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats.

Authors:  Vera Bubenikova-Valesova; Jan Svoboda; Jiri Horacek; Tomiki Sumiyoshi
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

3.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.

Authors:  Ling Lan; Yu-Long Chen; Hao Zhang; Bai-Ling Jia; Yan-Jun Chu; Jin Wang; Shi-Xiao Tang; Guo-Dong Xia
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

4.  Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis.

Authors:  Masayoshi Mori; Yusuke Murata; Asami Matsuo; Tomoyo Takemoto; Kazunori Mine
Journal:  Neurol Ther       Date:  2014-01-03

Review 5.  Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.

Authors:  Xuefei Huang; Jing Yang; Sijin Yang; Shousong Cao; Dalian Qin; Ya Zhou; Xiaoli Li; Yun Ye; Jianming Wu
Journal:  Oncotarget       Date:  2017-10-27

6.  Relative Safety and Efficacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled Trial.

Authors:  Qingwei Li; Haiyin Zhang; Guozhen Lin; Shenxun Shi; Yingli Zhang; Jianlin Ji; Lipeng Yang; Jun Yao; Wenyuan Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-08       Impact factor: 2.989

7.  Tandospirone prevents stress-induced anxiety-like behavior and visceral hypersensitivity by suppressing theta oscillation enhancement via 5-HT1A receptors in the anterior cingulate cortex in rats.

Authors:  Ting-Ting Zhan; Zhi-Yu Dong; Li-Sha Yi; Yan Zhang; Hui-Hui Sun; Hai-Qin Zhang; Jun-Wen Wang; Ying Chen; Ying Huang; Shu-Chang Xu
Journal:  Front Cell Neurosci       Date:  2022-08-22       Impact factor: 6.147

8.  5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home.

Authors:  Shinichiro Ochi; Takaaki Mori; Jun-Ichi Iga; Shu-Ichi Ueno
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-08-31       Impact factor: 2.582
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.